跳至主要内容
临床试验/NCT02978456
NCT02978456已完成不适用

Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation: GUIDE-DES Trial

CHEOL WHAN LEE, M.D., Ph.D6 个研究点 分布在 1 个国家目标入组 1,528 人开始时间: 2017年2月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,528
试验地点
6
主要终点
Target lesion failure

研究概览

简要总结

The purpose of this study is to compare clinical outcomes between quantitative coronary angiography -guided and Intravascular ultrasound -guided strategy in patients with significant coronary artery disease undergoing sirolimus-eluting Orsiro/Orsiro mission stent implantation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men or women at least 19years of age
  • Typical chest pain or objective evidence of myocardial ischemia suitable for elective PCI
  • Significant coronary artery lesions suitable for sirolimus-eluting Orsiro/Orsiro mission stent implantation
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

排除标准

  • Angiographic exclusion criteria: any of the followings 1)Bypass graft lesions 2)Impaired delivery of IVUS is expected:
  • Extreme angulation (≥90°) proximal to or within the target lesion.
  • Excessive tortuosity (≥ two 45° angles) proximal to or within the target lesion.
  • Heavy calcification proximal to or within the target lesion.
  • Previous percutaneous coronary intervention within 6 months before the index procedure
  • Previous BVS (bioresorbable vascular scaffold) implantation
  • Left ventricular ejection fraction (LVEF) < 30%
  • Hypersensitivity or contraindication to device material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated.
  • Persistent thrombocytopenia (platelet count <100,000/µl)
  • Any history of hemorrhagic stroke or intracranial hemorrhage, Transient ischemic attack or ischemic stroke within the past 6 months
  • A known intolerance to antiplatelet agents (aspirin, clopidogrel, prasugrel or ticagrelor)
  • Any surgery requiring general anesthesia or discontinuation of aspirin and/or an ADP antagonist is planned within 12 months after the procedure.
  • A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer.
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.
  • Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal).
  • Life expectancy < 1 years for any non-cardiac or cardiac causes
  • Unwillingness or inability to comply with the procedures described in this protocol.
  • Patient's pregnant or breast-feeding or child-bearing potential.

结局指标

主要结局

Target lesion failure

时间窗: 12 months

the cumulative incidence of cardiac death, target vessel myocardial infarction or ischemia-driven target lesion revascularization at 12 months after the index procedure.

次要结局

  • Target lesion revascularization(12 months)
  • Myocardial infarction(12 months)
  • Economic analysis(12 months)
  • Death (cardiac, vascular, non-cardiovascular)(12 months)
  • Procedural success(24 hours)
  • Stent thrombosis (definite/probable)(12 months)
  • Stroke(12 months)
  • Any revascularization(12 months)

研究者

发起方
CHEOL WHAN LEE, M.D., Ph.D
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

CHEOL WHAN LEE, M.D., Ph.D

professor, Division of Cardiology, Department of Internal Medicine

Asan Medical Center

研究点 (6)

Loading locations...

相似试验